logo-header-min.png
Marker Therapeutics Reports Fiscal Year 2021 Operating and Financial Results
March 17, 2022 17:45 ET | Marker Therapeutics
Enrollment of first 20 patients of the Company’s Phase 2 acute myeloid leukemia (AML) trial completed in Q4 2021 Topline readout of Group 2 active disease anticipated in Q2 2022 Company plans to...
logo-header-min.png
Marker Therapeutics to Present at Two Upcoming March Investor Conferences
March 07, 2022 16:05 ET | Marker Therapeutics
HOUSTON, March 07, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based...
logo-header-min.png
Marker Therapeutics Announces Clinical Program Updates and Pipeline Expansion
February 16, 2022 16:30 ET | Marker Therapeutics
Results from safety lead-in stage of Marker’s Phase 2 AML trial demonstrate that MT-401 was well-tolerated, eliminated measurable residual disease (MRD) in one MRD+ patient and induced epitope...
logo-header-min.png
Marker Therapeutics to Host Clinical Program Update Conference Call and Webcast on Wednesday, February 16, 2022
February 08, 2022 16:05 ET | Marker Therapeutics
HOUSTON, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based...
logo-header-min.png
Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Pancreatic Cancer
January 19, 2022 16:49 ET | Marker Therapeutics
HOUSTON, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based...